Dr. Bruix on Regorafenib in Second-Line HCC

Name: Dr. Bruix on Regorafenib in Second-Line HCC
Uploaded: 2017-01-17T02:26:34.000Z
Description: Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses positive results with the use of regorafenib as a second-line treatment in patients previously treated with sorafenib in advanced hepatocellular carcinoma.

January 16, 2017

Jordi Bruix, MD

Video

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses positive results with the use of regorafenib as a second-line treatment in patients previously treated with sorafenib in advanced hepatocellular carcinoma.

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses positive results with the use of regorafenib (Stivarga) as a second-line treatment in patients previously treated with sorafenib (Nexavar) in advanced hepatocellular carcinoma (HCC).

Multiple failed trials over the past 10 years finally came to an end when the RESORCE phase III trial resulted in a reduction in the risk of death. In this randomized trial, overall survival was significantly improved with regorafenib plus best supportive care versus placebo plus best supportive care (HR, 0.62; 95% CI, 0.50-0.78; P <.001). Based on these data, the FDA recently granted a priority review to regorafenib in this setting.

The discovery of the benefits of regorafenib as a second-line treatment comes at a great time in liver cancer treatment, says Bruix, as the field had become pessimistic in the years following the approval of sorafenib.